The Food and Drug Administration (FDA) issued an alert about a brand of cough syrup containing hydrocodone, a potent narcotic that could be abused if not used correctly...
The Food and Drug Administration (FDA) issued an alert about a brand of cough syrup containing hydrocodone, a potent narcotic that could be abused if not used correctly.
Tussionex Pennkinetic Extended-Release Suspension is a prescription product, indicated for adults and children 6 and older, once every six hours. FDA reported that serious adverse reactions, including death, have been reported in patients taking more than the indicated dose. Some patients even did so on their physician's advice.
FDA recommended that Tussionex be contraindicated for anyone younger than 6, that patients be told how often and in what quantity to take the medicine, and that they use a syringe instead of a teaspoon for dosing.
Tussionex's manufacturer, UCB, will update its labeling accordingly.
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.